Clinical Trials Browser

Phase 3 × Recruiting × daratumumab × Clear all

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05438043 2026-03-16

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT05552222 2026-03-12

MajesTEC-7

Phase 3 Recruiting

Multiple Myeloma

NCT05623020 2026-03-04

MagnetisMM-6

Phase 3 Recruiting

Multiple Myeloma

NCT03937635 2026-03-02

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Phase 3 Recruiting

Smoldering Multiple Myeloma

NCT04566328 2026-03-02

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

Multiple Myeloma

NCT05020236 2026-02-02

MAGNETISMM-5

Phase 3 Recruiting

Multiple Myeloma

NCT06932562 2026-01-23

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Phase 3 Recruiting

Multiple Myeloma

NCT06679101 2026-01-08

DREAMM-10

Phase 3 Recruiting

Multiple Myeloma

NCT06464991 2025-07-20

FUMANBA-03

Phase 3 Recruiting

Multiple Myeloma

NCT06867991 2025-07-15

RADIA

Phase 3 Recruiting

Autoimmune Diseases of the Nervous System, Anti-N-Methyl-D-Aspartate Receptor Encephalitis

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Phase 3 Recruiting

Multiple Myeloma

NCT06187441 2024-08-19

HOVON174MM

Phase 3 Recruiting

Multiple Myeloma

NCT06296121 2024-03-06

DARVIVA

Phase 3 Recruiting

Multiple Myeloma